About: Immunogenicity and Protection from Receptor-Binding Domains of Toxins as Potential Vaccine Candidates for Clostridium difficile

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunogenicity and Protection from Receptor-Binding Domains of Toxins as Potential Vaccine Candidates for Clostridium difficile Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunogenicity and Protection from Receptor-Binding Domains of Toxins as Potential Vaccine Candidates for Clostridium difficile
Creator	Wang, Hui Xing, Li Luo, Deyan Zhang, Liangyan Huang, Jie Li, Jiajia Liu, Xuechao Sun, Yakun
Source	Medline; PMC
abstract	The receptor-binding domains (RBDs) located in toxin A and toxin B of Clostridium difficile are known to be nontoxic and immunogenic. We need to develop a new type vaccine based on RBDs. In this study, we expressed and purified recombinant proteins (named RBD-TcdA and RBD-TcdB) as vaccine candidates containing the RBDs of toxin A and toxin B, respectively, from the C. difficile reference strain VPI10463. The immunogenicity and protection of the vaccine candidates RBD-TcdA, RBD-TcdB, and RBD-TcdA/B was evaluated by ELISA and survival assays. The data indicated that mice immunized with all vaccine candidates displayed potent levels of RBD-specific serum IgG. Following intramuscular immunization of mice with RBD-TcdA and/or RBD-TcdB, these vaccine candidates triggered immune responses that protected mice compared to mice immunized with aluminum hydroxide alone. Taken together, the results of this study reveal that recombinant proteins containing RBDs of C. difficile toxins can be used for vaccine development. Additionally, we found that an RBD-TcdA/B vaccine can elicit a stronger humoral immune response and provide better immunoprotection than the univalent vaccines. This RBD vaccine candidate conferred significant protection against disease symptoms and death caused by toxins from a wild-type C. difficile strain.
has issue date	2019-11-08(xsd:dateTime)
bibo:doi	10.3390/vaccines7040180
bibo:pmid	31717334
has license	cc-by
sha1sum (hex)	14626b4b98947a5534bdcc578b6659c258f7e7dd
schema:url	https://doi.org/10.3390/vaccines7040180
resource representing a document's title	Immunogenicity and Protection from Receptor-Binding Domains of Toxins as Potential Vaccine Candidates for Clostridium difficile
has PubMed Central identifier	PMC6963439
has PubMed identifier	31717334
schema:publication	Vaccines (Basel)
resource representing a document's body	covid:14626b4b98947a5534bdcc578b6659c258f7e7dd#body_text
is schema:about of	named entity 'POTENTIAL' named entity 'TAKEN' named entity 'CONTAINING' named entity 'TCDA' named entity 'SERUM' named entity 'INDICATED' named entity 'TRIGGERED' named entity 'IMMUNIZED' named entity 'C. DIFFICILE' named entity 'VACCINES' named entity 'VACCINE DEVELOPMENT' named entity 'DISPLAYED' named entity 'IMMUNIZATION' named entity 'SPECIFIC' named entity 'ALUMINUM HYDROXIDE' named entity 'SIGNIFICANT' named entity 'USED' named entity 'TOXIN A' named entity 'STRAIN' named entity 'RESULTS' named entity 'IMMUNOGENICITY' named entity 'BETTER' named entity 'HUMORAL IMMUNE RESPONSE' named entity 'VACCINE' named entity 'FOLLOWING' named entity 'TOXIN B' named entity 'IMMUNOPROTECTION' named entity 'WILD-TYPE' named entity 'BINDING' named entity 'RECEPTOR' named entity 'DEATH' named entity 'TOXINS' named entity 'INTRAMUSCULAR' named entity 'SYMPTOMS' named entity 'SURVIVAL' named entity 'IMMUNOGENIC' named entity 'IMMUNOGENICITY' named entity 'COMPARED' named entity 'PROTECTION' named entity 'PURIFIED' named entity 'CAUSED BY' named entity 'IMMUNE RESPONSES' named entity 'NEED' named entity 'CLOSTRIDIUM DIFFICILE' named entity 'PROTECTION' named entity 'ELISA' named entity 'STUDY' named entity 'LOCATED IN' named entity 'NEW TYPE' named entity 'REVEAL' named entity 'NONTOXIC' named entity 'THESE' named entity 'KNOWN' named entity 'DATA' named entity 'TYPE C' named entity 'EVALUATED' named entity 'VACCINE' named entity 'TOXINS' named entity 'BASED' named entity 'PROVIDE' named entity 'ELICIT' named entity 'EXPRESSED' named entity 'MICE' named entity 'CLOSTRIDIUM DIFFICILE' named entity 'REFERENCE' named entity 'RECOMBINANT PROTEINS' named entity 'LEVELS' named entity 'RECEPTOR' named entity 'BINDING' named entity 'VACCINE CANDIDATE' named entity 'IGG' named entity '2FB' named entity 'TCDB' named entity 'DISEASE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software